United States Patent 7,364,752: Ritonavir Solid-Dispersion Claims, Expiration, and Patent Landscape

U.S. Patent 7,364,752 protects pharmaceutical compositions in which ritonavir is present as an amorphous solid dispersion within a water-soluble polymer matrix. The strongest commercial limitation is the requirement for amorphous ritonavir dispersed in the polymer matrix. Claims covering PEG, PEG 8000, gelatin capsules, tablets, excipients, ground dispersions, lopinavir combinations, and HIV-treatment methods narrow the base composition claim.

The patent was assigned to Abbott Laboratories, later associated with AbbVie’s Norvir and Kaletra products. Its patent term ran from the relevant 1997 priority period and expired in December 2017. The patent therefore does not currently create an enforceable U.S. exclusivity barrier. Its technical disclosures remain relevant to formulation design and freedom-to-operate analysis, particularly for ritonavir-lopinavir products.

What does U.S. Patent 7,364,752 protect?

The patent protects a formulation architecture rather than ritonavir as a chemical entity.

The central claim requires all of the following:

A pharmaceutical composition.
Ritonavir.
Ritonavir formulated as a solid dispersion.
Ritonavir in an amorphous state.
A matrix that includes a water-soluble polymer.

Claim 1 is the independent composition claim. The term “comprising” makes the claim open-ended. A formulation may contain additional active ingredients, excipients, coatings, buffers, or dosage-form components without avoiding the claim, provided the required ritonavir dispersion is present.

The claim does not require a specific dosage strength, route of administration, particle size, release profile, or ratio of ritonavir to polymer. It also does not limit the water-soluble polymer to PEG. Claims 4 and 5 identify PEG and PEG 8000 as narrower embodiments.

What is the key technical limitation?

The key limitation is the amorphous solid dispersion.

A simple physical mixture of crystalline ritonavir and PEG would not satisfy the claim’s express requirement for “amorphous ritonavir” formulated as a “solid dispersion.” A formulation containing amorphous ritonavir outside a polymer matrix also presents a substantial non-infringement position.

The product would normally be assessed using solid-state and formulation characterization, including:

Powder X-ray diffraction.
Differential scanning calorimetry.
Infrared or Raman spectroscopy.
Microscopy.
Dissolution testing.
Polymer and active-ingredient distribution analysis.
Stability testing for recrystallization.

The patent’s commercial purpose was to address ritonavir’s poor aqueous solubility and the formation of a more stable, bioavailable formulation. The amorphous state can improve dissolution, but it may also create physical-stability risks if ritonavir recrystallizes during storage.

How do the claims differ in scope?

Claim	Subject matter	Scope
1	Ritonavir amorphous solid dispersion in a water-soluble polymer matrix	Broadest composition claim
2	Claim 1 in a gelatin capsule	Capsule-specific narrowing
3	Claim 1 in a tablet	Tablet-specific narrowing
4	Claim 1 where the polymer is PEG	PEG formulation
5	Claim 1 where the polymer is PEG 8000	Specific PEG grade
6	Claim 1 also containing ABT-378	Ritonavir-lopinavir combination
7	Claim 1 with filler, diluent, lubricant, or disintegrant	Conventional dosage-form excipients
8	Ground solid dispersion formulated into a delivery system	Particle-processing and delivery-system limitation
9	HIV treatment using claim 1 composition	Method-of-treatment claim
10	HIV treatment using claim 6 composition	Method claim for ritonavir-ABT-378 combination

What is ABT-378 in claim 6?

ABT-378 is lopinavir, the protease inhibitor used with ritonavir in Kaletra. Claim 6 therefore covers a combination in which ritonavir is formulated as the claimed amorphous solid dispersion and the composition also contains lopinavir.

The claim does not necessarily require lopinavir to be in the same physical phase or the same dispersion as ritonavir. The phrase “said solid dispersion further comprises” creates a claim-construction issue. A challenger could argue that claim 6 requires lopinavir to be part of the solid dispersion itself. The patent owner could argue that the claim requires the composition, rather than the polymeric dispersion alone, to contain both active ingredients. The product’s manufacturing process and the location of lopinavir in the finished dosage form would be important.

When did U.S. Patent 7,364,752 lose exclusivity?

The patent expired in December 2017 based on the relevant priority and filing history. No current U.S. patent exclusivity is attributable to Patent 7,364,752.

Milestone	Date or status
Subject matter	Ritonavir amorphous solid dispersion
Original assignee	Abbott Laboratories
Patent number	U.S. 7,364,752
Issue date	April 29, 2008
Patent term basis	Twenty-year term from the earliest relevant nonprovisional filing
Expiration	December 2017
Current enforceability	Expired
Patent term extension	No operative extension is generally associated with this patent
Regulatory exclusivity	Expired separately from patent rights

The expiration of the patent does not invalidate other patents covering ritonavir, lopinavir, manufacturing processes, crystalline forms, dosing regimens, or unrelated formulations.

What is the Orange Book status of U.S. Patent 7,364,752?

The patent was associated with the Norvir and/or Kaletra formulation patent estate during the period in which those products received U.S. regulatory protection. Its present Orange Book significance is limited because the patent has expired.

The Orange Book separates patent listing from enforceability. A listed patent can remain visible in historical records after expiration, but an expired patent cannot support a current injunction against a generic applicant. FDA listing also does not decide claim construction or infringement.

Norvir was approved under NDA 20-659 in 1996. Kaletra was approved under NDA 21-226 in 2000. Patent protection and FDA marketing exclusivity for those products operated on separate timelines. The five-year new chemical entity exclusivity associated with ritonavir and the three-year clinical-investigation exclusivity associated with later products expired long before the 7,364,752 patent term ended. FDA, Drugs@FDA, and the Orange Book should be used together because NDA-level patent records and product-level regulatory exclusivity are distinct datasets.[1][2]

What patents are relevant to the ritonavir and lopinavir patent estate?

Patent 7,364,752 was one component of a broader estate. The principal related U.S. rights include the following.

Patent	General subject matter	Commercial relevance	Status
U.S. 5,541,206	Ritonavir compound and related pharmaceutical uses	Core ritonavir protection	Expired
U.S. 5,914,332	Lopinavir and HIV protease-inhibitor combinations	Historical Kaletra compound and combination protection	Expired
U.S. 6,037,157	Ritonavir pharmaceutical formulation subject matter	Norvir formulation protection	Expired
U.S. 6,593,367	Ritonavir formulation and solid-dispersion technology	Related formulation estate	Expired
U.S. 7,364,752	Amorphous ritonavir in a water-soluble polymer matrix	PEG and dosage-form formulation protection	Expired

The exact claim overlap among these patents depends on the product and the asserted claim. A generic ritonavir tablet could avoid 7,364,752 while still implicating a different formulation, process, or method-of-use patent. Conversely, a formulation that reproduces the patented amorphous dispersion would have faced a direct product-claim issue during the patent term.

What formulation patents are protected by the patent?

Claims 2, 3, 4, 5, 7, and 8 create a formulation-focused perimeter around the broad claim.

Gelatin capsules

Claim 2 covers a gelatin capsule containing the claimed dispersion. The claim does not appear to require a particular capsule size, shell composition, fill weight, or capsule-release profile. A non-gelatin capsule would fall outside the literal scope of claim 2 but could still fall within claim 1.

Tablets

Claim 3 covers tablets containing the dispersion. It does not require direct compression, wet granulation, a particular coating, or a specific disintegration time. A tablet can therefore be covered even if its manufacturing process differs from the disclosed examples, assuming the finished product contains the required amorphous dispersion.

PEG and PEG 8000

Claims 4 and 5 narrow the polymer limitation. PEG 8000 is a specific embodiment of the broader “water soluble polymer” category. Other water-soluble polymers may remain within claim 1, including polymers with materially different molecular weights or chemical structures, depending on their role in forming the dispersion.

A formulation using a water-insoluble polymer, lipid carrier, cyclodextrin complex, nanocrystal, or crystalline ritonavir would present a stronger design-around position, although the complete claim set and doctrine of equivalents would still require review.

Excipients

Claim 7 covers conventional excipients such as fillers, diluents, lubricants, and disintegrants. Because claim 1 is already open-ended, claim 7 has limited incremental breadth. Its value is evidentiary and litigation-oriented: it confirms that ordinary tableting ingredients do not remove the composition from the claim.

Ground dispersions

Claim 8 adds grinding and formulation into a delivery system. This claim is narrower than claim 1 and may be difficult to apply where the finished product contains a dispersion but the manufacturer does not use the claimed grinding step. Claim 8 also raises proof issues concerning process records and the physical identity of the ground material.

What generic entry risks existed during the patent term?

During the term, a generic applicant seeking approval for a product containing amorphous ritonavir in a water-soluble polymer could have faced a Paragraph IV certification and infringement action under the Hatch-Waxman Act.

The principal risk factors were:

Whether the ANDA product used amorphous rather than crystalline ritonavir.
Whether the active ingredient was dispersed within a water-soluble polymer matrix.
Whether the polymer was PEG or PEG 8000.
Whether the product was a tablet or capsule.
Whether the product also contained lopinavir.
Whether the patent was listed for the relevant NDA and dosage form.
Whether the ANDA applicant relied on a Paragraph IV certification or a section viii carve-out for method claims.

A Paragraph IV challenge would have triggered a potential 30-month stay if the patent owner filed suit within the statutory period. That mechanism expired with the patent. A later generic applicant could seek approval without facing a viable infringement action based solely on Patent 7,364,752.

Which companies challenged Norvir or Kaletra exclusivity?

The relevant competitive field included generic pharmaceutical companies seeking approval for ritonavir, lopinavir, or lopinavir-ritonavir products. Publicly reported generic activity has involved companies such as Lupin, Mylan, Hetero, and other ANDA sponsors across different formulations and markets.

Patent-specific attribution must distinguish:

Challenges to the ritonavir active ingredient.
Challenges to lopinavir-ritonavir combinations.
Challenges to liquid formulations.
Challenges to tablets.
Challenges to formulation patents.
Non-U.S. opposition or invalidity proceedings.
Voluntary licensing and public-health supply arrangements.

An ANDA or generic launch does not establish that Patent 7,364,752 was invalid. The patent’s current expiration makes that distinction historical rather than commercially dispositive.

What patent litigation and settlements affected the estate?

The principal U.S. litigation risk during the term was the standard Hatch-Waxman dispute over whether an ANDA product reproduced the claimed amorphous dispersion. The relevant legal questions would have included infringement, validity, written description, enablement, obviousness, anticipation, and the scope of the term “solid dispersion.”

Potential validity attacks would focus on:

Prior art describing amorphous ritonavir.
Prior art using PEG or another water-soluble polymer.
Whether the claimed combination produced an unexpected dissolution or stability result.
Whether the patent specification enabled the full breadth of claim 1.
Whether the claims adequately described the claimed amorphous dispersion.

No settlement can eliminate the public expiration date. A settlement could have permitted an earlier generic launch, but it would not extend the patent term. Product-specific settlements involving Kaletra or Norvir should be reviewed separately from the patent record because confidential launch dates and covenants may not appear in the patent file.

How strong is the patent estate for a current ritonavir product?

Patent 7,364,752 has no current blocking strength because it is expired. Its historical strength was moderate to high against products that deliberately reproduced the PEG-based amorphous ritonavir technology.

Issue	Assessment
Claim breadth	Broad at the composition level, but dependent on amorphous solid-dispersion proof
Technical detectability	Moderate; solid-state testing can identify amorphous and dispersed material
Design-around potential	Moderate to high
Method-claim value	Limited after product patent expiration and difficult to enforce against prescribing
Combination coverage	Narrower, focused on ritonavir with lopinavir
Current U.S. blocking value	None
Historical litigation leverage	Material for matching formulations
Global value	Dependent on corresponding national patents, which may have expired at different times

How does this patent compare with core ritonavir and lopinavir patents?

The distinction is straightforward.

Core compound patents protect the chemical entity and generally provide earlier, broader pharmaceutical exclusivity.
Combination patents protect ritonavir with lopinavir or other active ingredients.
Formulation patents protect physical form, polymer matrix, dosage form, or manufacturing architecture.
Method patents protect treatment uses, dosing, or patient populations.

Patent 7,364,752 was narrower than a compound patent but more directly relevant to a competing finished dosage form. Its commercial importance came from formulation replication, not from control of ritonavir itself.

Does the patent create biosimilar risk?

No. Ritonavir and lopinavir are small-molecule drugs, not biologics. The applicable competitive pathway is the ANDA pathway for generic drugs, not the abbreviated pathway under section 351(k) for biosimilars.

A generic applicant would evaluate therapeutic equivalence, bioequivalence, pharmaceutical equivalence, patent certifications, and any listed exclusivity. Biosimilar interchangeability standards do not apply.

What manufacturing and intellectual-property barriers remain?

The expired patent does not prevent manufacture of the claimed dispersion in the United States. Commercial barriers may still exist in:

Controlling amorphous-state stability.
Preventing recrystallization.
Achieving consistent polymer distribution.
Maintaining dissolution performance.
Scaling hot-melt, solvent, or grinding operations.
Controlling residual solvents.
Meeting content-uniformity specifications.
Demonstrating bioequivalence for a complex formulation.

Those barriers are technical and regulatory rather than enforceable rights under Patent 7,364,752. Separate active patents, trade secrets, manufacturing know-how, regulatory exclusivities, and third-party licenses must be evaluated independently.

Key Takeaways

U.S. Patent 7,364,752 covers amorphous ritonavir formulated as a solid dispersion in a water-soluble polymer matrix.
Claim 1 is the principal claim; claims 2 through 8 narrow the dosage form, polymer, excipients, processing, or active-ingredient combination.
Claim 6 specifically reaches compositions containing ritonavir and lopinavir, identified in the claim as ABT-378.
The patent expired in December 2017 and does not provide current U.S. exclusivity.
The patent was historically important for Norvir and Kaletra formulation protection.
A simple crystalline ritonavir formulation, non-dispersed amorphous ritonavir, or a formulation using a materially different delivery technology could present a design-around position.
Current generic risk must be assessed against other active patents and regulatory requirements, not this expired patent.
Ritonavir and lopinavir are small molecules; biosimilar law is not applicable.
The remaining commercial barriers are formulation performance, manufacturing control, bioequivalence, and any separate active intellectual-property rights.

FAQs

Can a generic manufacturer use PEG 8000 with ritonavir today?

Yes, Patent 7,364,752 no longer blocks that formulation in the United States. The manufacturer must still address other active patents, FDA requirements, bioequivalence, and product-quality controls.

Does the patent cover crystalline ritonavir mixed with PEG?

Not literally under claim 1. The claim requires amorphous ritonavir formulated as a solid dispersion in the polymer matrix.

Is lopinavir the same compound as ABT-378?

Yes. ABT-378 is the development designation identified with lopinavir, the second active ingredient in Kaletra.

Could claim 9 be used against a physician prescribing ritonavir?

Method-of-treatment claims can raise separate enforcement issues, but claim 9 is expired. Its practical blocking value is therefore zero in the United States.

Are Kaletra and Norvir covered by the same patent estate?

They shared portions of the ritonavir-related estate, but their complete patent portfolios were not identical. Kaletra also implicated lopinavir compound, combination, formulation, and regulatory records.

References

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Patent No. 5,541,206. (1996). Ritonavir, a process for its preparation and pharmaceutical compositions containing it. United States Patent and Trademark Office.
U.S. Patent No. 5,914,332. (1999). Antiviral compounds and pharmaceutical compositions. United States Patent and Trademark Office.
U.S. Patent No. 6,037,157. (2000). Pharmaceutical compositions comprising ritonavir. United States Patent and Trademark Office.
U.S. Patent No. 6,593,367. (2003). Pharmaceutical compositions comprising ritonavir. United States Patent and Trademark Office.
U.S. Patent No. 7,364,752. (2008). Pharmaceutical compositions comprising ritonavir. United States Patent and Trademark Office.

Details for Patent: 7,364,752

Summary for Patent: 7,364,752